TW202423421A - 預防或改善衰弱用之組成物，及抑制或改善高齡所伴隨之身體活動力降低用之組成物 - Google Patents
預防或改善衰弱用之組成物，及抑制或改善高齡所伴隨之身體活動力降低用之組成物 Download PDFInfo
- Publication number
- TW202423421A TW202423421A TW112130758A TW112130758A TW202423421A TW 202423421 A TW202423421 A TW 202423421A TW 112130758 A TW112130758 A TW 112130758A TW 112130758 A TW112130758 A TW 112130758A TW 202423421 A TW202423421 A TW 202423421A
- Authority
- TW
- Taiwan
- Prior art keywords
- composition
- ergothioneine
- frailty
- present
- salt
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 77
- 208000036119 Frailty Diseases 0.000 title claims abstract description 46
- 206010003549 asthenia Diseases 0.000 title claims abstract description 46
- 230000037081 physical activity Effects 0.000 title claims abstract description 36
- 230000032683 aging Effects 0.000 title claims abstract description 24
- 230000007423 decrease Effects 0.000 title claims abstract description 23
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 claims abstract description 101
- 229940093497 ergothioneine Drugs 0.000 claims abstract description 71
- 150000003839 salts Chemical class 0.000 claims abstract description 45
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 235000013305 food Nutrition 0.000 claims description 27
- 208000016285 Movement disease Diseases 0.000 claims description 22
- 230000002401 inhibitory effect Effects 0.000 claims description 18
- 230000037361 pathway Effects 0.000 claims description 8
- 241000244206 Nematoda Species 0.000 description 26
- 239000003814 drug Substances 0.000 description 22
- 229940079593 drug Drugs 0.000 description 19
- 101100369572 Caenorhabditis elegans mpst-1 gene Proteins 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- 230000036541 health Effects 0.000 description 14
- 230000004083 survival effect Effects 0.000 description 8
- 208000012661 Dyskinesia Diseases 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 6
- 230000002354 daily effect Effects 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 230000006866 deterioration Effects 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- -1 inorganic acid salts Chemical class 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 240000001462 Pleurotus ostreatus Species 0.000 description 4
- 235000001603 Pleurotus ostreatus Nutrition 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 244000251953 Agaricus brunnescens Species 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 229940126701 oral medication Drugs 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 241000222350 Pleurotus Species 0.000 description 2
- 235000007685 Pleurotus columbinus Nutrition 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 150000008043 acidic salts Chemical class 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 159000000011 group IA salts Chemical class 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 244000045069 Agrocybe aegerita Species 0.000 description 1
- 235000008121 Agrocybe aegerita Nutrition 0.000 description 1
- 241000404030 Anacyclus clavatus Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241001489124 Boletus edulis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000244202 Caenorhabditis Species 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 244000191482 Cantharellus cibarius Species 0.000 description 1
- 235000015722 Cantharellus cibarius Nutrition 0.000 description 1
- 102000020018 Cystathionine gamma-Lyase Human genes 0.000 description 1
- 108010045283 Cystathionine gamma-lyase Proteins 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241001167795 Escherichia coli OP50 Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 240000001080 Grifola frondosa Species 0.000 description 1
- 235000007710 Grifola frondosa Nutrition 0.000 description 1
- 240000000588 Hericium erinaceus Species 0.000 description 1
- 235000007328 Hericium erinaceus Nutrition 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 235000001715 Lentinula edodes Nutrition 0.000 description 1
- 244000141359 Malus pumila Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000002769 Morchella esculenta Species 0.000 description 1
- 235000002779 Morchella esculenta Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000392443 Pleurotus citrinopileatus Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000004385 Sulfurtransferases Human genes 0.000 description 1
- 108090000984 Sulfurtransferases Proteins 0.000 description 1
- 238000001790 Welch's t-test Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000004503 fine granule Substances 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022130122 | 2022-08-17 | ||
| JP2022-130122 | 2022-08-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202423421A true TW202423421A (zh) | 2024-06-16 |
Family
ID=89941602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW112130758A TW202423421A (zh) | 2022-08-17 | 2023-08-16 | 預防或改善衰弱用之組成物，及抑制或改善高齡所伴隨之身體活動力降低用之組成物 |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JPWO2024038821A1 (https=) |
| CN (1) | CN119604289A (https=) |
| TW (1) | TW202423421A (https=) |
| WO (1) | WO2024038821A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2024172003A1 (https=) * | 2023-02-16 | 2024-08-22 | ||
| WO2025063190A1 (ja) * | 2023-09-19 | 2025-03-27 | 株式会社エル・エスコーポレーション | エルゴチオネインを含有する組成物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7681882B2 (ja) * | 2019-10-03 | 2025-05-23 | 学校法人沖縄科学技術大学院大学学園 | フレイルの判定方法 |
| JPWO2022230487A1 (https=) * | 2021-04-26 | 2022-11-03 |
-
2023
- 2023-08-10 WO PCT/JP2023/029205 patent/WO2024038821A1/ja not_active Ceased
- 2023-08-10 CN CN202380056126.8A patent/CN119604289A/zh active Pending
- 2023-08-10 JP JP2024541532A patent/JPWO2024038821A1/ja active Pending
- 2023-08-16 TW TW112130758A patent/TW202423421A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2024038821A1 (https=) | 2024-02-22 |
| CN119604289A (zh) | 2025-03-11 |
| WO2024038821A1 (ja) | 2024-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW202423421A (zh) | 預防或改善衰弱用之組成物，及抑制或改善高齡所伴隨之身體活動力降低用之組成物 | |
| JP2024069498A (ja) | エルゴチオネイン又はその塩を含有する睡眠改善用組成物 | |
| TW202308613A (zh) | 用於抑制腎功能降低或改善腎功能之組成物 | |
| CN115867289B (zh) | 含有nr及/或nmn与芝麻素类的组合物 | |
| TW202308615A (zh) | 促進免疫細胞之代謝用之組成物 | |
| WO2022230487A1 (ja) | 赤血球及び／又はヘモグロビン増加用組成物 | |
| TW202200129A (zh) | 菸鹼醯胺腺嘌呤二核苷酸（ｎａｄ）濃度上昇劑 | |
| JP7796118B2 (ja) | 白血球及び／又は好塩基球増加用組成物 | |
| CN116322370A (zh) | 抗疲劳用组合物及用于能量产生能的提高、降低抑制或维持的组合物 | |
| US20250017905A1 (en) | Composition for inhibiting histamine-n-methyltransferase | |
| HK40124129A (zh) | 预防或改善衰弱用组合物，以及用於抑制或改善伴随年龄增长的身体活动能力下降的组合物 | |
| KR20070095338A (ko) | 간기능 개선제 | |
| CN117241680A (zh) | 脂肪分解促进用组合物 | |
| TW202448445A (zh) | 含有麥角硫因之肌肉萎縮抑制用組成物及Ｓｒｃ酪胺酸激酶阻礙用組成物 | |
| TWI888414B (zh) | 生活活動量之維持、預防降低、抑制降低或改善用組成物之使用 | |
| WO2024172002A1 (ja) | エルゴチオネインを含有する血管拡張用組成物 | |
| WO2024203675A1 (ja) | エルゴチオネイン又はその塩を含有する熱中症又は脱水症を予防、軽減又は改善するための組成物及び細胞内外水分を調節するための組成物 | |
| TW202502321A (zh) | 含有芝麻素類化合物及阿魏酸或其鹽之組成物 | |
| HK40089668A (zh) | 含有nr及/或nmn与芝麻素类的组合物 |